How expensive is denosumab?
|Drug/Comparator||Strength||Average Annual Drug Cost ($)|
|Denosumab (Xgeva)||120 mg||7,482|
|Pamidronate (Aredia)^||30 mg/10 mL 60 mg/10 mL 90 mg/10 mL||6,510 to 8,680|
|Pamidronate (generic)^||30 mg/10 mL 60 mg/10 mL 90 mg/10 mL||1,182 to 1,577|
|Zoledronic acid (Zometa)||4 mg/5 mL||7,203 to 9,604|
Is denosumab better than zoledronic acid?
Denosumab and zoledronic acid are both bone-modifying agents that prevent the occurrence of SREs. Denosumab has been shown to be superior to zoledronic acid in delaying SREs in various types of cancer, such as breast cancer, lung cancer, and multiple myeloma.
Is denosumab better than Zometa?
A study has found that Xgeva (chemical name: denosumab), a targeted therapy medicine, is better than Zometa at reducing the risk of a skeletal-related event in women diagnosed with metastatic breast cancer that has spread to the bones. The study also found Xgeva improved quality of life more than Zometa.
Is there an alternative to zoledronic acid?
medwireNews: Phase III study data show that the RANKL-targeting monoclonal antibody denosumab is noninferior to zoledronic acid for the prevention of bone disease in patients with newly diagnosed multiple myeloma.
Is zoledronic acid more effective than denosumab for osteoporosis?
Comparison of the efficacy, adverse effects, and cost of zoledronic acid and denosumab in the treatment of osteoporosis The denosumab group had a higher mean increase in spine BMD, and the ZA group had a higher incidence of flu-like symptoms, but the study groups were statistically similar in terms of patient satisfaction.
Does denosumab reduce skeletal-related event prevention in bone-metastatic prostate cancer?
Objective: Denosumab has been approved in the US for skeletal-related event (SRE) prevention in bone-metastatic prostate cancer on the basis of a phase III clinical trial in which denosumab reduced SREs relative to zoledronic acid. Overall survival, disease progression, and serious adverse events did not differ significantly between groups.
What are the possible adverse effects of denosumab and Za?
Methods: The charts of patients who received denosumab and ZA at Loyola Hospital were reviewed, and adverse events were noted. Of primary interest were myalgias, flu-like symptoms, back pain, and fractures.
Does denosumab increase spine BMD at 1 year?
Results: The study cohort consisted of 107 patients (51 denosumab, 56 ZA). The denosumab group had a greater mean increase in spine BMD at 1 year (0.060 g/cm2) than the ZA group (0.021 g/cm2; P = .04).